Sarcopenia Market on Track for Major Expansion by 2034, According to DelveInsight | Biophytis, MyMD Pharma, N12: Erasmus Medical Center, Erasmus Medical Center, Novartis, Regeneron Pharmaceuticals

The Key Sarcopenia Companies in the marlet include - Biophytis, MyMDPharmaceuticals, Inc, N12: Erasmus Medical Center, Erasmus Medical Center, Novartis, Regeneron Pharmaceuticals, Merck Sharp & Dohme LLC, Lipocine Inc., and others.
DelveInsight's "Sarcopenia Market Insights, Epidemiology, and Market Forecast-2034 report offers an in-depth understanding of the Sarcopenia, historical and forecasted epidemiology as well as the Sarcopenia market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.

To Know in detail about the Sarcopenia market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Sarcopenia Market Forecast [https://www.delveinsight.com/sample-request/sarcopenia-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]

Some of the key facts of the Sarcopenia Market Report:

*
The Sarcopenia market size was valued ~USD 2,796 million in 2023 and is anticipated to grow with a significant CAGR during the study period (2020-2034)

*
In 2023, the United States had the largest market size for Sarcopenia among the 7MM, reaching around USD 1,826 million, with an anticipated growth at a CAGR of 6.3%.

*
In 2023, France had the largest market size for Sarcopenia among the EU countries, with approximately USD 150 million, while Spain had the smallest market size, around USD 55 million.

*
In 2023, the market size for Sarcopenia in Japan was approximately USD 434 million.

*
The total market size for Sarcopenia is anticipated to change in the coming years with the expected launch of new therapies, including Sarconeos (BIO101) and MYMD-1, among others.

*
According to DelveInsight's assessment, the total diagnosed prevalent cases of Sarcopenia across the 7MM were estimated to be approximately 27 million in 2023.

*
In 2023, the US accounted for the highest proportion of diagnosed prevalent cases of Sarcopenia, with approximately 56%, and this number is expected to increase in the future.

*
In 2023, France reported the highest number of diagnosed prevalent cases of Sarcopenia among European countries, with approximately 2 million cases, followed by Italy with around 1.9 million cases. In contrast, Spain had the lowest prevalence, with about 0.7 million cases.

*
In 2023, Japan reported approximately 5.2 million diagnosed prevalent cases of Sarcopenia, representing around 19% of the total cases across the 7MM.

*
In 2023, the majority of Sarcopenia cases in the US were classified as mild to moderate severity, with approximately 13 million cases.

*
Key Sarcopenia Companies: Biophytis, MyMDPharmaceuticals, Inc, N12: Erasmus Medical Center, Erasmus Medical Center, Novartis, Regeneron Pharmaceuticals, Merck Sharp & Dohme LLC, Lipocine Inc., and others

*
Key Sarcopenia Therapies: Sarconeos(BIO101), MYMD-1, Olimel, N12, bimagrumab, REGN1033 (SAR391786), MK-0773, MYMD-1, LPCN 1148, and others

*
The Sarcopenia market is expected to surge due to the disease's increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Sarcopenia pipeline products will significantly revolutionize the Sarcopenia market dynamics.

Sarcopenia Overview

Sarcopenia is a condition characterized by the gradual loss of muscle mass, strength, and function, typically associated with aging. It can lead to physical frailty, reduced mobility, and an increased risk of falls and fractures. Sarcopenia is often diagnosed through a combination of muscle mass measurements and assessments of strength or physical performance. It can be influenced by factors such as inactivity, poor nutrition, chronic illness, and hormonal changes. Early detection and management through exercise, diet, and, in some cases, medication, can help mitigate its effects.

Get a Free sample for the Sarcopenia Market Forecast, Size & Share Analysis Report:

https://www.delveinsight.com/report-store/sarcopenia-market [https://www.delveinsight.com/report-store/sarcopenia-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]

Sarcopenia Epidemiology

The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2020 to 2034. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.

Sarcopenia Epidemiology Segmentation:

The Sarcopenia market report proffers epidemiological analysis for the study period 2020-2034 in the 7MM segmented into:

*
Total Prevalence of Sarcopenia

*
Prevalent Cases of Sarcopenia by severity

*
Gender-specific Prevalence of Sarcopenia

*
Diagnosed Cases of Episodic and Chronic Sarcopenia

Download the report to understand which factors are driving Sarcopenia epidemiology trends @ Sarcopenia Epidemiology Forecast [https://www.delveinsight.com/sample-request/sarcopenia-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]

Sarcopenia Drugs Uptake and Pipeline Development Activities

The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Sarcopenia market or expected to get launched during the study period. The analysis covers Sarcopenia market uptake by drugs, patient uptake by therapies, and sales of each drug.

Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.

The report also covers the Sarcopenia Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

Sarcopenia Therapies and Key Companies

*
Sarconeos(BIO101): Biophytis

*
MYMD-1: MyMDPharmaceuticals, Inc.

*
Olimel N12: Erasmus Medical Center

*
bimagrumab: Novartis

*
REGN1033 (SAR391786): Regeneron Pharmaceuticals

*
MK-0773: Merck Sharp & Dohme LLC

*
MYMD-1: MyMD Pharmaceutical

*
LPCN 1148: Lipocine Inc.

Discover more about therapies set to grab major Sarcopenia market share @ Sarcopenia Treatment Landscape [https://www.delveinsight.com/sample-request/sarcopenia-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]

Sarcopenia Market Strengths

*
Lifestyle modifications, including exercise and proper nutrition, have shown efficacy in preventing and managing sarcopenia.

Sarcopenia Market Opportunities

*
Improved integration of sarcopenia screening and management into routine healthcare practices can enhance early detection and intervention.

Scope of the Sarcopenia Market Report

*
Study Period: 2020-2034

*
Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]

*
Key Sarcopenia Companies: Biophytis, MyMDPharmaceuticals, Inc, N12: Erasmus Medical Center, Erasmus Medical Center, Novartis, Regeneron Pharmaceuticals, Merck Sharp & Dohme LLC, Lipocine Inc., and others

*
Key Sarcopenia Therapies: Sarconeos(BIO101), MYMD-1, Olimel, N12, bimagrumab, REGN1033 (SAR391786), MK-0773, MYMD-1, LPCN 1148, and others

*
Sarcopenia Therapeutic Assessment: Sarcopenia current marketed and Sarcopenia emerging therapies

*
Sarcopenia Market Dynamics: Sarcopenia market drivers and Sarcopenia market barriers

*
Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies

*
Sarcopenia Unmet Needs, KOL's views, Analyst's views, Sarcopenia Market Access and Reimbursement

To know more about Sarcopenia companies working in the treatment market, visit @ Sarcopenia Clinical Trials and Therapeutic Assessment [https://www.delveinsight.com/sample-request/sarcopenia-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]

Table of Contents

1. Sarcopenia Market Report Introduction

2. Executive Summary for Sarcopenia

3. SWOT analysis of Sarcopenia

4. Sarcopenia Patient Share (%) Overview at a Glance

5. Sarcopenia Market Overview at a Glance

6. Sarcopenia Disease Background and Overview

7. Sarcopenia Epidemiology and Patient Population

8. Country-Specific Patient Population of Sarcopenia

9. Sarcopenia Current Treatment and Medical Practices

10. Sarcopenia Unmet Needs

11. Sarcopenia Emerging Therapies

12. Sarcopenia Market Outlook

13. Country-Wise Sarcopenia Market Analysis (2020-2034)

14. Sarcopenia Market Access and Reimbursement of Therapies

15. Sarcopenia Market Drivers

16. Sarcopenia Market Barriers

17. Sarcopenia Appendix

18. Sarcopenia Report Methodology

19. DelveInsight Capabilities

20. Disclaimer

21. About DelveInsight

About DelveInsight

DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Gaurav Bora
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=sarcopenia-market-on-track-for-major-expansion-by-2034-according-to-delveinsight-biophytis-mymd-pharma-n12-erasmus-medical-center-erasmus-medical-center-novartis-regeneron-pharmaceuticals]
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/



This release was published on openPR.